Wall Street brokerages expect Karyopharm Therapeutics Inc. (NASDAQ:KPTI) to report $370,000.00 in sales for the current quarter, according to Zacks. Three analysts have issued estimates for Karyopharm Therapeutics’ earnings. The lowest sales estimate is $50,000.00 and the highest is $1.00 million. Karyopharm Therapeutics posted sales of $60,000.00 during the same quarter last year, which would indicate a positive year-over-year growth rate of 516.7%. The business is expected to report its next earnings results on Thursday, August 3rd.
On average, analysts expect that Karyopharm Therapeutics will report full year sales of $370,000.00 for the current fiscal year, with estimates ranging from $70,000.00 to $1.07 million. For the next year, analysts anticipate that the firm will post sales of $79.17 million per share, with estimates ranging from $44.97 million to $113.37 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side analysts that follow Karyopharm Therapeutics.
Karyopharm Therapeutics (NASDAQ:KPTI) last issued its quarterly earnings results on Thursday, May 4th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.67) by $0.04. The business had revenue of $0.07 million during the quarter, compared to the consensus estimate of $0.02 million. Karyopharm Therapeutics had a negative return on equity of 72.41% and a negative net margin of 50,646.40%. During the same quarter in the previous year, the business earned ($0.75) earnings per share.
A number of analysts recently weighed in on KPTI shares. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $18.00 price objective on shares of Karyopharm Therapeutics in a research note on Monday, May 15th. Wedbush reaffirmed an “outperform” rating and issued a $14.00 price objective on shares of Karyopharm Therapeutics in a research note on Wednesday, April 5th. Robert W. Baird reaffirmed an “outperform” rating and issued a $15.00 price objective on shares of Karyopharm Therapeutics in a research note on Thursday, April 6th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $14.00 price objective on shares of Karyopharm Therapeutics in a research note on Monday, March 13th. Finally, ValuEngine lowered shares of Karyopharm Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, May 25th. One analyst has rated the stock with a sell rating, eight have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $14.56.
TRADEMARK VIOLATION WARNING: “$370,000.00 in Sales Expected for Karyopharm Therapeutics Inc. (KPTI) This Quarter” was posted by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this news story on another website, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The legal version of this news story can be read at https://sportsperspectives.com/2017/07/20/370000-00-in-sales-expected-for-karyopharm-therapeutics-inc-kpti-this-quarter-updated.html.
A number of institutional investors have recently made changes to their positions in the company. Teza Capital Management LLC purchased a new position in shares of Karyopharm Therapeutics during the first quarter worth approximately $169,000. American International Group Inc. increased its position in shares of Karyopharm Therapeutics by 20.9% in the first quarter. American International Group Inc. now owns 16,422 shares of the company’s stock worth $211,000 after buying an additional 2,836 shares in the last quarter. C WorldWide Group Holding A S increased its position in shares of Karyopharm Therapeutics by 30.2% in the first quarter. C WorldWide Group Holding A S now owns 16,928 shares of the company’s stock worth $217,000 after buying an additional 3,928 shares in the last quarter. Metropolitan Life Insurance Co. NY increased its position in shares of Karyopharm Therapeutics by 12.6% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 21,911 shares of the company’s stock worth $206,000 after buying an additional 2,460 shares in the last quarter. Finally, Parametric Portfolio Associates LLC increased its position in shares of Karyopharm Therapeutics by 38.6% in the first quarter. Parametric Portfolio Associates LLC now owns 27,988 shares of the company’s stock worth $359,000 after buying an additional 7,789 shares in the last quarter. Institutional investors and hedge funds own 57.11% of the company’s stock.
Shares of Karyopharm Therapeutics (NASDAQ KPTI) traded down 1.90% on Friday, hitting $9.30. 111,806 shares of the company traded hands. The firm’s 50-day moving average is $9.29 and its 200 day moving average is $10.20. Karyopharm Therapeutics has a 1-year low of $6.27 and a 1-year high of $14.63. The firm’s market capitalization is $438.20 million.
Karyopharm Therapeutics Company Profile
Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Karyopharm Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.